Intest Res.  2018 Apr;16(2):321-322. 10.5217/ir.2018.16.2.321.

Author's Reply

• Hiraoka S
• Kato J
• Okada H

• KMID: 2417688
• DOI: http://doi.org/10.5217/ir.2018.16.2.321

Abstract

No abstract available.

MeSH Terms

Tumor Necrosis Factor-alpha
Crohn Disease
Adrenal Cortex Hormones
Tumor Necrosis Factor-alpha
Adrenal Cortex Hormones

Reference

1. Kotze PG, Ma C, Regueiro M, Panaccione R. The old versus the new: which do you keep in postoperative Crohn's disease? Intest Res. 2018; 16:319–320.

2. Hiraoka S, Takashima S, Kondo Y, et al. Efficacy of restarting anti-tumor necrosis factor alpha agents after surgery in patients with Crohn's disease. Intest Res. 2018; 16:75–82. PMID: 29422801.

3. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013; 108:40–47. PMID: 23147525.

4. Gisbert JP, Marín AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015; 41:613–623. PMID: 25652884.

5. Zorzi F, Zuzzi S, Onali S, et al. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study. Aliment Pharmacol Ther. 2012; 35:1397–1407. PMID: 22519466.

6. Campos C, Perrey A, Lambert C, et al. Medical therapies for stricturing Crohn's disease: efficacy and cross-sectional imaging predictors of therapeutic failure. Dig Dis Sci. 2017; 62:1628–1636. PMID: 28401425.